Potentia To Present ASaP Phase I Clinical Trial Data For POT-4 At The American Academy Of Ophthalmology Annual Meeting | OphthalmologyWeb: The Ultimate Online Resource for Ophthalmologists

Tuesday, October 28, 2008

Email

Comments

Medical News Today

Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that the Company will be presenting its ASaP Phase I clinical data for its leading drug candidate, POT-4, during the Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) Annual Meeting in Atlanta, GA, on November 7, 2008.

Retina Products and Equipment »

A 45 y.o. female comes to the office with a chief complaint of tearing ou and foreign body sensation. Of note are small superficial punctate epitheliopathy diffusely over the central cornea. Her tear film is scanty ou. One would expect her Schirmer’s test
1. >15mm with anesthetic
2. < 10mm="" with="" />
3. >20mm without anesthetic
4. <5mm without="">
Check The Answer

3nethra classic Ophthalmic Imaging Device
The 3nethra classic is a compact, ... view product
OPMI LUMERA 700 Surgical Microscope
OPMI LUMERA 700 Incorporating the latest... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us